Filing Flows › Medifast (MED) › Q2 2026 › vs Q2 2025
Medifast (MED) Q2 2026 vs Q2 2025 (year over year)
Medifast's revenue fell $29.2M (-28%) from $106M in Q2 2025 to $76.4M in Q2 2026.
Medifast, Q2 2026: revenue $76.4M (-28% year over year), operating margin -5.7%, net loss $3.1M, operating cash flow $1.7M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 1.0% | -4.5% | +5.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $76.4M | $106M | −$29.2M | -28% |
| Other income, net | $1.3M | $3.9M | −$2.6M | -66% |
| Net loss | $3.1M | −$2.5M | $5.6M | — |
| Costs & expenses | $80.8M | $109M | −$28.7M | -26% |
| Operating costs | $80.7M | $107M | −$25.9M | -24% |
| Income tax | $109K | $395K | −$286K | -72% |
| Cost of revenue | $23.0M | $28.9M | −$5.9M | -20% |
| Operating expenses | $57.7M | $77.7M | −$20.0M | -26% |
| Operating cash sources | $5.3M | $6.7M | −$1.4M | -21% |
| Depreciation & amortization | $3.4M | $4.0M | −$599K | -15% |
| Share-based compensation | $1.8M | $2.6M | −$809K | -31% |
| Net loss absorbed | $3.1M | −$2.5M | $5.6M | — |
| Working capital & other | $467K | $12.5M | −$12.1M | -96% |
| Operating cash flow | $1.7M | −$3.4M | $5.1M | — |
| Free cash flow (OCF − capex) | $728K | −$4.8M | $5.5M | — |
| Capital expenditures | $969K | $1.4M | −$409K | -30% |
Questions
How much did Medifast's revenue grow year over year in Q2 2026?
Medifast's revenue fell $29.2M (-28%) from $106M in Q2 2025 to $76.4M in Q2 2026.